Pharmaceutical

Syneos Health Stockholders Approve Agreement with Private Investment Consortium

MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading…

11 months ago

Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing…

11 months ago

RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE…

11 months ago

Aridis Pharmaceuticals Announces $2 Million Offering

Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the…

11 months ago

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel…

11 months ago

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…

11 months ago

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in…

11 months ago

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company…

11 months ago

Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with…

11 months ago

Medexus Schedules First Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host…

11 months ago